Regulatory
🇪🇺 EMAEMA news and analysis for pharmaceutical BD, investment, and market access
Navigate global pharma regulatory landscapes. Get critical intelligence on FDA, EMA, and global drug approval pathways for strategic decision-making.
Showing 1–12 of 38 articles
Quick answer
NovaPharmaNews Regulatory hub for EMA covers 38 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
MHRA targets medicine safety with new AI sandbox
EMA approves TX01 PIP, unlocking the PUMA pathway for Theranexus and Exeltis
KRX IR Reference : Executive Summary Plan for SCD NDR (ENG, Jun 2026)
EC nod for Chiesi Lojuxta for pediatric HoFH: what it means for pharma
Regulatory round-up: 2 February 2026 – EMA opinions, FDA approvals, and what they mean for pharma
Novel Muscle-Active Agents: A Regulatory Perspective on Sarcopenia
The Baker Company Benelux BV joins EuropaBio: Advancing cell culture and lab safety technologies
Japan Grants Orphan Status to QRX003 for Netherton Syndrome: Implications for Pharma Teams
데일리팜 리크루트: Vyloy (zolbetuximab) Reimbursement Progress and Market Implications for Gastric Cancer
Cancer Therapy OST-HER2 Faces 2026 EMA Call After Survival Data
Kaléo's Initiative on Allergy Awareness: Amplifying Patient Stories
Pharma People on the Move: Spring 2026 Roundup — Regulatory Updates
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.